Carbon monoxide exposure improves immune function in lupus-prone mice

Immunology

Volumn 140, Issue 1, 2013, Pages 123-132

  Mackern Oberti, Juan P ^a   Llanos, Carolina ^a,b   Carreño, Leandro J ^a   Riquelme, Sebastián A ^a   Jacobelli, Sergio H ^a,b   Anegon, Ignacio ^c   Kalergis, Alexis M ^a,b,c  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c Centre National de la Recherche Scientifique   (France)

Author keywords

Carbon monoxide; Haem oxygenase 1; Systemic lupus erythematosus

Indexed keywords

CARBON MONOXIDE; CARBOXYHEMOGLOBIN; CD11B ANTIGEN; FC RECEPTOR IIB; HEME OXYGENASE 1; HISTONE ANTIBODY; PROTOPORPHYRIN COBALT; PROTOPORPHYRIN TIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNITY; CELL EXPANSION; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME INDUCTION; EXPERIMENTAL MODEL; EXPOSURE; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; KIDNEY INJURY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; SYSTEMIC LUPUS ERYTHEMATOSUS;

CARBON MONOXIDE; HAEM OXYGENASE-1; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIGENS, CD11B; AUTOIMMUNITY; CARBON MONOXIDE; DISEASE MODELS, ANIMAL; ENZYME INDUCTION; FEMALE; HEME OXYGENASE-1; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEMBRANE PROTEINS; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, IGG; SPLEEN; T-LYMPHOCYTES, REGULATORY;

EID: 84883239274     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12124     Document Type: Article

References (51)

1. Rekvig OP, Nossent JC. Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms? Arthritis Rheum 2003; 48:300-12.
2. Brown EE, Edberg JC, Kimberly RP. Fc receptor genes and the systemic lupus erythematosus diathesis. Autoimmunity 2007; 40:567-81.
3. Anolik JH. B cell biology and dysfunction in SLE. Bull NYU Hosp Jt Dis 2007; 65:182-6.
4. Cohen PLPL. T- and B-cell abnormalities in systemic lupus. J Invest Dermatol 1993; 100:69S-72S.
5. Sanz I, Lee FE-H. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6:326-37.
6. Ronnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6:339-47.
7. Crispin JC, Kyttaris VC, Terhorst C, Tsokos GC. T cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6:317-25.
8. Katsiari CG, Liossis S-NC, Sfikakis PP. The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: a reappraisal. Semin Arthritis Rheum 2010; 39:491-503.
9. Gaipl US, Munoz LE, Grossmayer G et al. Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun 2007; 28:114-21.
10. Muñoz LE, Janko C, Grossmayer GE et al. Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum 2009; 60:1733-42.
11. Sullivan KE, Suriano A, Dietzmann K, Lin J, Goldman D, Petri MA. The TNFα locus is altered in monocytes from patients with systemic lupus erythematosus. Clin Immunol 2007; 123:74-81.
12. Figueroa-Vega N, Galindo-Rodríguez G, Bajaña S, Portales-Pérez D, Abud-Mendoza C, Sánchez-Torres C, González-Amaro R. Phenotypic analysis of IL-10-treated, monocyte-derived dendritic cells in patients with systemic lupus erythematosus. Scand J Immunol 2006; 64:668-76.
13. Kikuchi S, Santiago-Raber M-L, Amano H, Amano E, Fossati-Jimack L, Moll T, Kotzin BL, Izui S. Contribution of NZB autoimmunity 2 to Y-linked autoimmune acceleration-induced monocytosis in association with murine systemic lupus. J Immunol 2006; 176:3240-7.
14. Müller M, Emmendörffer A, Lohmann-Matthes M-L. Expansion and high proliferate potential of the macrophage system throughout life time of lupus-prone NZB/W and MRL lpr/lpr mice. Lack of down-regulation of extramedullar macrophage proliferation in the postnatal period. Eur J Immunol 1991; 21:2211-7.
15. Santiago-Raber M-L, Amano H, Amano E et al. Fcγ receptor-dependent expansion of a hyperactive monocyte subset in lupus-prone mice. Arthritis Rheum 2009; 60:2408-17.
16. Kuroiwa T, Lee EG. Cellular interactions in the pathogenesis of lupus nephritis: the role of T cells and macrophages in the amplification of the inflammatory process in the kidney. Lupus 1998; 7:597-603.
17. Frosch M, Vogl T, Waldherr R, Sorg C, Sunderkötter C, Roth J. Expression of MRP8 and MRP14 by macrophages is a marker for severe forms of glomerulonephritis. J Leukoc Biol 2004; 75:198-206.
18. Houssiau FA, Ginzler EM. Current treatment of lupus nephritis. Lupus 2008; 17:426-30.
19. Abraham NG, Kappas A. Pharmacological and clinical aspects of hemeoxygenase. Pharmacol Rev 2008; 60:79-127.
20. Rémy S, Blancou P, Tesson L et al. Carbon monoxide inhibits TLR-induced dendritic cell immunogenicity. J Immunol 2009; 182:1877-84.
21. + T cells and protect from type 1 diabetes. Eur J Immunol 2013; 43:209-18.
22. Listopad J, Asadullah K, Sievers C, Ritter T, Meisel C, Sabat R, Döcke W-D. Heme oxygenase-1 inhibits T cell-dependent skin inflammation and differentiation and function of antigen-presenting cells. Exp Dermatol 2007; 16:661-70.
23. Chora ÂA, Fontoura P, Cunha A et al. Hemeoxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J Clinl Invest 2007; 117:438-47.
24. Moreau A, Hill M, Thébault P et al. Tolerogenic dendritic cells actively inhibit T cells through heme oxygenase-1 in rodents and in nonhuman primates. FASEB J 2009; 23:3070-7.
25. Takeda Y, Takeno M, Iwasaki M et al. Chemical induction of HO-1 suppresses lupus nephritis by reducing local iNOS expression and synthesis of anti-dsDNA antibody. Clin Exp Immunol 2004; 138:237-44.
26. Blancou P, Tardif V, Simon T, Rémy S, Carreño L, Kalergis A, Anegon I. Immunoregulatory Properties of Heme Oxygenase-1. In: Cuturi MC, Anegon I, eds. Suppression and Regulation of Immune Responses SE - 18. NY: Humana Press, 2011: 677 247-68.
27. Kapturczak MH, Wasserfall C, Brusko T, Campbell-Thompson M, Ellis TM, Atkinson MA, Agarwal A. Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse. Am J Pathol 2004; 165:1045-53.
28. Herrada AA, Llanos C, Mackern-Oberti JP et al. Haemoxygenase 1 expression is altered in monocytes from patients with systemic lupus erythematosus. Immunology 2012; 136:414-24.
29. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV. Augmented humoral and anaphylactic responses in FcγRII-deficient mice. Nature 1996; 379:346-9.
30. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcγ receptors on dendritic cells. J Exp Med 2002; 195:1653-9.
31. Li M, Kim DH, Tsenovoy PL et al. Treatment of obese diabetic mice with a hemeoxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes 2008; 57:1526-35.
32. Cai Y, Cho G-S, Ju C et al. Activated microglia are less vulnerable to hemin toxicity due to nitric oxide-dependent inhibition of JNK and p38 MAPK activation. J Immunol 2011; 187:1314-21.
33. Riquelme SA, Bueno SM, Kalergis AM. IgG keeps virulent Salmonella from evading dendritic cell uptake. Immunology 2012; 136:291-305.
34. high T cells in patients with new-onset systemic lupus erythematosus. Clin Exp Immunol 2008; 153:182-7.
35. Miyara M, Amoura Z, Parizot C et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005; 175:8392-400.
36. Gerli R, Nocentini G, Alunno A, Bocci EB, Bianchini R, Bistoni O, Riccardi C. Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun Rev 2009; 8:426-30.
37. Muller S, Dieker J, Tincani A, Meroni PL. Pathogenic anti-nucleosome antibodies. Lupus 2008; 17:431-6.
38. Yachie A, Toma T, Mizuno K, Okamoto H, Shimura S, Ohta K, Kasahara Y, Koizumi S. Heme oxygenase-1 production by peripheral blood monocytes during acute inflammatory illnesses of children. Exp Biol Med 2003; 228:550-6.
39. Liu B, Tan W, Barsoum A et al. IL-17 is a potent synergistic factor with GM-CSF in mice in stimulating myelopoiesis, dendritic cell expansion, proliferation, and functional enhancement. Exp Hematol 2010; 38:877-84.
40. Yoshimoto K, Tanaka M, Kojima M et al. Regulatory mechanisms for the production of BAFF and IL-6 are impaired in monocytes of patients of primary Sjögren's syndrome. Arthritis Res Ther 2011; 13:R170.
41. Hora K, Satriano JA, Santiago A, Mori T, Stanley ER, Shan Z, Schlondorff D. Receptors for IgG complexes activate synthesis of monocyte chemoattractant peptide 1 and colony-stimulating factor 1. Proc Natl Acad Sci U S A 1992; 89:1745-9.
42. Ryter SW, Alam J, Choi AMK. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 2006; 86:583-650.
43. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8:958-69.
44. Ribechini E, Greifenberg V, Sandwick S, Lutz M. Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol 2010; 199:273-81.
45. + T cell-mediated suppression by dendritic cells. Science 2003; 299:1033-6.
46. + regulatory T cells. J Immunol 2011; 186:32-40.
47. Chauveau C, Rémy S, Royer PJ et al. Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood 2005; 106:1694-702.
48. Galbraith RA, Kappas A. Regulation of food intake and body weight in rats by the synthetic heme analogue cobalt protoporphyrin. Am J Physiol 1991; 261:R1388-94.
49. Rosenberg DW, Drummond GS, Smith TJ. Depletion of cytochrome P-450 by thyroid hormone and cobalt-protoporphyrin IX in rat liver: evidence that susceptibility varies among forms of the hemeprotein. Pharmacology 1995; 51:254-62.
50. Reilly CM, Farrelly LW, Viti D et al. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int 2002; 61:839-46.
51. Fujii M, Inoguchi T, Sasaki S, Maeda Y, Zheng J, Kobayashi K, Takayanagi R. Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase. Kidney Int 2010; 78:905-19.